Board Member
Nuvectis Pharma, Inc. (NVCT)Equibles does not estimate personal net worth.
Get an email with a short summary when Nuvectis Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get NVCT alertsRon Bentsur is recorded as Board Member at Nuvectis Pharma, Inc. (NVCT) since January 1, 2020 and CEO at Nuvectis Pharma, Inc. (NVCT). The newest filing on record that lists Ron Bentsur as CEO and Board Member at Nuvectis Pharma, Inc. (NVCT) is dated April 27, 2026. Nuvectis Pharma, Inc. reported in an 8-K filed June 16, 2023 that Ron Bentsur was appointed Class I director, effective June 16, 2023. The proxy statement of Nuvectis Pharma, Inc. reports total compensation of $2,588,526 for Ron Bentsur in fiscal 2025, including a base salary of $653,987. Disclosed compensation is on record for 5 fiscal years. Ron Bentsur has spoken on 1 earnings call and 3 other investor events across 1 company, most recently for Nuvectis Pharma, Inc. on November 4, 2026. Nuvectis Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nuvectis Pharma, Inc. includes James Oliviero (Board Member), Juan Sanchez (Board Member), Juan Sanchez, MD (Board Member) and 2 others.
“The votes with respect to the election of the Class I director to hold office until the 2026 annual meeting were as follows:”
“Before we begin, I would like to remind everyone that statements made during this call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.”
“And thank you, H.C. Wainwright, for inviting us to present at the conference. It's very nice to be here. And I'll dive right into the Novectus Pharma story. So just a couple of words about the background of the founders of the company.”
“Following our safe harbor statement, I will review the details of the strategic in-licensing deal that we announced earlier this morning. Before we begin, I'd like to remind everyone on this call that we'll be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.”
“So for five minutes in my life, it can be taller than you. But the, so it's a very important question. So all these biomarkers and all these mutations, Fortunately for us, we don't need to come up with a companion diagnostic, that would be pretty horrific.”
2020-01-01–present
Last confirmed April 27, 2026
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
CEO, Board Member
2020-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Nuvectis Pharma, Inc. (NVCT) | Chairman & CEO | $653,987 | $2,588,526 |
| 2024 | Nuvectis Pharma, Inc. (NVCT) | President & Chief Executive Officer | $634,323 | $1,157,639 |
| 2023 | Nuvectis Pharma, Inc. (NVCT) | President & Chief Executive Officer | $615,250 | $2,690,725 |
| 2022 | Nuvectis Pharma, Inc. (NVCT) | President & Chief Executive Officer | $420,360 | $1,694,010 |
| 2021 | Nuvectis Pharma, Inc. (NVCT) | President, Chief Executive Officer and Director | — | $384,018 |
